20.20
price down icon2.88%   -0.60
 
loading
Schlusskurs vom Vortag:
$20.80
Offen:
$20.58
24-Stunden-Volumen:
2.69M
Relative Volume:
1.04
Marktkapitalisierung:
$2.56B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-10.00
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-9.74%
1M Leistung:
+24.00%
6M Leistung:
+45.22%
1J Leistung:
+33.95%
1-Tages-Spanne:
Value
$19.82
$20.68
1-Wochen-Bereich:
Value
$19.82
$22.71
52-Wochen-Spanne:
Value
$6.78
$23.56

10 X Genomics Inc Stock (TXG) Company Profile

Name
Firmenname
10 X Genomics Inc
Name
Telefon
(925) 401-7300
Name
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Name
Mitarbeiter
1,306
Name
Twitter
@10xgenomics
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TXG's Discussions on Twitter

Vergleichen Sie TXG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Health Information Services icon
TXG
10 X Genomics Inc
20.20 2.63B 631.73M -239.78M -33.45M -2.02
Health Information Services icon
VEEV
Veeva Systems Inc
203.92 34.52B 3.08B 860.33M 1.35B 5.1463
Health Information Services icon
TEM
Tempus Ai Inc
59.82 11.30B 803.32M -709.10M -212.68M -7.8003
Health Information Services icon
HQY
Healthequity Inc
85.67 7.14B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
BTSG
Brightspring Health Services Inc
39.27 7.18B 11.99B 24.18M 234.31M 0.2956
Health Information Services icon
DOCS
Doximity Inc
37.47 7.27B 550.17M 201.35M 232.07M 1.00

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-11 Herabstufung Citigroup Buy → Neutral
2025-12-02 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-09-11 Eingeleitet Piper Sandler Neutral
2025-02-13 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-03 Eingeleitet Leerink Partners Outperform
2024-07-22 Hochstufung Jefferies Hold → Buy
2024-07-18 Herabstufung JP Morgan Overweight → Neutral
2024-07-10 Herabstufung Deutsche Bank Buy → Hold
2024-06-27 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-25 Herabstufung Guggenheim Buy → Neutral
2024-06-03 Fortgesetzt Jefferies Hold
2024-05-01 Herabstufung TD Cowen Buy → Hold
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-12-12 Hochstufung BofA Securities Underperform → Neutral
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-05-10 Eingeleitet Barclays Overweight
2023-03-31 Eingeleitet Stephens Overweight
2023-02-02 Eingeleitet UBS Neutral
2022-12-14 Eingeleitet Deutsche Bank Buy
2022-08-18 Herabstufung Goldman Neutral → Sell
2022-07-25 Eingeleitet Canaccord Genuity Buy
2022-07-15 Herabstufung BofA Securities Neutral → Underperform
2022-07-15 Herabstufung William Blair Outperform → Mkt Perform
2021-10-15 Fortgesetzt Cowen Outperform
2021-09-14 Herabstufung BofA Securities Buy → Neutral
2021-03-15 Eingeleitet William Blair Outperform
2020-12-02 Eingeleitet Goldman Neutral
2020-09-09 Eingeleitet Morgan Stanley Overweight
2020-07-10 Eingeleitet Stifel Buy
2020-03-05 Eingeleitet Guggenheim Buy
2020-01-07 Eingeleitet Citigroup Buy
2019-10-07 Eingeleitet BofA/Merrill Buy
2019-10-07 Eingeleitet Cowen Outperform
2019-10-07 Eingeleitet JP Morgan Overweight
2019-09-24 Eingeleitet Evercore ISI Outperform
Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

pulisher
08:33 AM

Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in 10x Genomics $TXG - MarketBeat

08:33 AM
pulisher
08:19 AM

AlphaQuest LLC Increases Holdings in 10x Genomics $TXG - MarketBeat

08:19 AM
pulisher
Jan 29, 2026

Is 10x Genomics Inc. still a buy after recent gainsPortfolio Profit Report & AI Enhanced Trading Signals - mfd.ru

Jan 29, 2026
pulisher
Jan 28, 2026

Stock Report: Will 10x Genomics Inc. outperform its industry peersJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru

Jan 28, 2026
pulisher
Jan 27, 2026

4 Best Genetic Sequencing Stocks To Buy in 2026 - The Motley Fool

Jan 27, 2026
pulisher
Jan 27, 2026

Breaking Down 10x Genomics: 13 Analysts Share Their Views - Benzinga

Jan 27, 2026
pulisher
Jan 24, 2026

10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected - simplywall.st

Jan 24, 2026
pulisher
Jan 23, 2026

Volume Report: How does 10x Genomics Inc perform in inflationary periods2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 23, 2026

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - BioSpace

Jan 23, 2026
pulisher
Jan 22, 2026

Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell - Yahoo Finance

Jan 22, 2026
pulisher
Jan 21, 2026

Revenue Check: What is VERX s P E ratio telling usAnalyst Upgrade & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 21, 2026

Inscription Capital LLC Acquires 59,305 Shares of 10x Genomics $TXG - MarketBeat

Jan 21, 2026
pulisher
Jan 20, 2026

10x Genomics (NASDAQ:TXG) Trading Up 8%Still a Buy? - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

10x Genomics Inc (TXG) Trading 6.38% Higher on Jan 20 - GuruFocus

Jan 20, 2026
pulisher
Jan 20, 2026

10X Genomics stock hits 52-week high of 21.52 USD - Investing.com

Jan 20, 2026
pulisher
Jan 20, 2026

Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? - Benzinga

Jan 20, 2026
pulisher
Jan 19, 2026

Sentiment Recap: Is 10x Genomics Inc a strong candidate for buy and hold2025 Momentum Check & Real-Time Buy Signal Alerts - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 18, 2026

Aug Breakouts: Is United States Steel Corporation stock a good pick for beginnersQuarterly Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 18, 2026

Aug Ideas: Can 10x Genomics Inc stock outperform in a bear marketJuly 2025 Closing Moves & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 18, 2026

Did 10x Genomics’ (TXG) Clinical Collaborations and CLIA Push Just Recast Its Investment Narrative? - simplywall.st

Jan 18, 2026
pulisher
Jan 15, 2026

Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

Aug Weekly: Whats the fair value of AN2 Therapeutics Inc stockWeekly Investment Summary & Technical Pattern Alert System - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 14, 2026

Wall Street Recap: What is INTA s revenue forecastTrade Performance Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 14, 2026

Insider Trends: Will 10x Genomics Inc outperform its industry peersJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance

Jan 13, 2026
pulisher
Jan 13, 2026

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - BioSpace

Jan 13, 2026
pulisher
Jan 13, 2026

Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail

Jan 13, 2026
pulisher
Jan 12, 2026

Why 10x Genomics (TXG) Shares Are Falling Today - Finviz

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics (NASDAQ:TXG) Shares Down 8.5%What's Next? - MarketBeat

Jan 12, 2026
pulisher
Jan 12, 2026

Cancer Research Institute Launches Transformative AI-Driven Immu - GuruFocus

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics partners with Dana-Farber to research cancer treatment responses - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics partners with Brigham & Women’s for autoimmune research - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics partners with Brigham & Women’s for autoimmune research By Investing.com - Investing.com Canada

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics Launches Study to Advance Research in Blood-Based D - GuruFocus

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics to Advance Research in Diagnostic Applications of T - GuruFocus

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - PR Newswire

Jan 12, 2026
pulisher
Jan 12, 2026

Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus

Jan 12, 2026
pulisher
Jan 12, 2026

10x Genomics sees uptick in Q4 revenue despite softer FY sales (TXG:NASDAQ) - Seeking Alpha

Jan 12, 2026
pulisher
Jan 11, 2026

10x Genomics (TXG) Achieves Remarkable Progress Despite Economic Challenges - GuruFocus

Jan 11, 2026
pulisher
Jan 11, 2026

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - The Malaysian Reserve

Jan 11, 2026
pulisher
Jan 11, 2026

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | TXG Stock News - Longbridge

Jan 11, 2026
pulisher
Jan 11, 2026

Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 32% - 富途牛牛

Jan 11, 2026
pulisher
Jan 10, 2026

Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

Aug Swings: Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда

Jan 10, 2026
pulisher
Jan 10, 2026

10x Genomics (NASDAQ:TXG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Jan 10, 2026
pulisher
Jan 10, 2026

Will 10x Genomics Inc. stock split attract more investorsJuly 2025 Highlights & Verified Swing Trading Watchlist - Улправда

Jan 10, 2026
pulisher
Jan 10, 2026

Published on: 2026-01-10 18:33:58 - moha.gov.vn

Jan 10, 2026
pulisher
Jan 09, 2026

10x Genomics (NASDAQ:TXG) Reaches New 12-Month HighShould You Buy? - MarketBeat

Jan 09, 2026
pulisher
Jan 09, 2026

10X Genomics stock hits 52-week high at 20.36 USD - Investing.com

Jan 09, 2026
pulisher
Jan 09, 2026

10X Genomics stock hits 52-week high at 20.36 USD By Investing.com - Investing.com India

Jan 09, 2026

Finanzdaten der 10 X Genomics Inc-Aktie (TXG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

10 X Genomics Inc-Aktie (TXG) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Taich Adam
Chief Financial Officer
Nov 24 '25
Sale
19.00
11,888
225,852
297,385
Hindson Benjamin J.
See Remarks
Nov 24 '25
Sale
19.00
8,283
157,363
432,605
Saxonov Serge
Chief Executive Officer
Nov 24 '25
Sale
19.00
13,261
251,936
1,021,556
$29.87
price down icon 3.08%
$34.90
price down icon 3.64%
$23.22
price up icon 1.53%
health_information_services WAY
$26.56
price down icon 0.56%
$37.47
price down icon 3.00%
Kapitalisierung:     |  Volumen (24h):